Navigation Links
GeNO LLC Announces Senior Management Appointment

WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- GeNO LLC, a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases, today announced that Kurt A. Dasse, Ph.D., currently serving as president and a member of the company's Board of Managers, has been appointed CEO of the Company.  Dr. David Fine will continue to serve GeNO as executive chairman and chief scientific officer.

"Dr. Dasse has significant international experience with the use of inhaled nitric oxide to minimize the risk of right heart failure following the treatment of patients undergoing the implantation of Left Ventricular Assist Devices (LVADs). This appointment will strengthen the company's focus on developing and obtaining regulatory approvals for its innovative and cost-effective platforms for generating nitric oxide therapy in the treatment of multiple diseases and conditions," said David Fine, GeNO founder and executive chairman. "I am thrilled to hand over the role of CEO to Kurt."

"I believe GeNO is well positioned to make a significant impact on the medical treatment of patients worldwide who suffer from pulmonary and cardiac diseases," said Dasse. "I am honored and excited to lead a highly talented group at GeNO committed to delivering the next generation of inhaled nitric oxide products, including a portable solution, designed to benefit a large patient population."

Dasse, who will continue to serve on the company's Board of Managers, has spent nearly 30 years researching and developing therapies for cardiopulmonary disorders, and has developed and commercialized devices and therapies for the treatment of heart, lung and renal failure. He joined GeNO as a member of the Board of Managers in 2007, and was appointed executive vice president in 2011 and president in 2012.

In 2001 Dasse co-founded Levitronix LLC, the developer of the CentriMag LVAD system, where he became president and CEO in 2006. Earlier in his career, Dasse was chief scientist and vice president of Thermo Electron Corporation's $700-million Biomedical Group. He was also one of the founding officers of Thermo Cardiosystems and played a key role in commercializing one of the first implantable ventricular assist systems for end-stage heart failure patients. Dasse received his doctorate in physiology from Boston University and his bachelor's degree in biology from the University of Massachusetts. He has written more than 100 journal articles and multiple book chapters, and holds numerous patents.


GeNO LLC is a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases.  GeNO is currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting.  GeNO's technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians and other end-users with a user-friendly solution.

CONTACT: Brian Heffron,
(781) 799-9568

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sihuan Pharmaceutical Announces 2013 Interim Results
2. Echo Therapeutics Announces Management Changes
3. ConvaTec Announces 2013 Second Quarter Earnings Call
4. Sam Solakyan, CEO of Vital Imaging Announces purchase of cutting edge equipment
5. Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
6. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
7. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
8. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
9. VirtualScopics Announces 1-for-10 Reverse Stock Split
10. Allscripts Announces Winners of the Open App Challenge
11. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):